|1. “On-label” or FDA-approved use|
|CYPHER Sirolimus-eluting Coronary Stent (5)|
|For improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions in native coronary arteries|
|TAXUS Express 2 Paclitaxel-Eluting Coronary Stent System (6)|
|For improving luminal diameter for the treatment of de novo lesions in native coronary arteries|
|2. “Off-label” or beyond FDA-approved use|
|High-risk patient subsets|
DES = drug-eluting stent; FDA = Food and Drug Administration; MI = myocardial infarction.